NCT03964103已完成不适用
Efficacy and Colon Attachment of gQ-lab Daily for Patients With Irritable Bowel Syndrome: Randomized, Double-blind, Placebo-controlled, Parallel-group Study
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 主要终点
- Symptom questionnaire survey (VAS score)
研究概览
简要总结
- Primary purpose: To assess satisfaction with overall improvement in symptoms, including individual bowel symptoms, after 4 weeks of administration of gQ-lab to patients with irritable bowel syndrome (IBS).
- Secondary purposes: To assess the correlation between intestinal attachment and therapeutic effects of gQ-lab through the visual analog scale (VAS) assessment of each IBS-related symptom and measurement of changes in quality of life and fecal flora in the placebo group and gQ-lab group after 4 weeks of gQ-lab administration.
To assess safety, including adverse reactions, vital signs (including weight), physical examination, and changes in blood test results.
To examine the rate of positive gut quotient (gQ) values in patients diagnosed with IBS as per the ROME III criteria. Further, to examine how the ROME III-based symptom scale score compared with that of the quality of life scale in the gQ questionnaire.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Korean men and women aged over 19 and 80
- •Patients with IBS meeting the ROME III criteria (Diagnosed with IBS with abdominal discomfort or abdominal pain in the past 3 months and meeting at least two of the following conditions: (1) improvement in defecation; (2) onset of symptoms associated with changes in stool frequency; (3) association with changes in stool form)
- •Patients who underwent colonoscopy in the past 5 years and have been confirmed to have no organ abnormalities
- •Women who are surgically infertile or fertile women who are negative during pregnancy diagnostic tests (urine or seron- hCG). Fertile women who have "almost no chance of becoming pregnant" during the study period owing to the use of appropriate contraception (e.g., oral contraceptive pills, IUD, double-barrier method, or hormone implants) or men who have agreed to this
- •People who have no problems in their nerves and mental systems and who can make their own doctors clear
- •The person who agreed in writing to this test
排除标准
- •Persons with hypersensitivity to probiotics
- •Pregnant or lactating women
- •People who have received other clinical trial drugs within the first 3 months of visit
- •(If the patient has received any other clinical trial drug within the past 3 months, contact the client's monitor to determine eligibility on a case-by-case basis.)
- •A person who believes that the participant is in a condition or situation in which participation in the clinical trial may be hazardous to the participant
- •Patients with severe congestive heart failure or severe angina
- •If the patient is diagnosed as having lactose intolerance or immunosuppression
- •Patients who are taking or taking medications (medicine for intestinal disorders, lactic acid bacteria) that may affect the test food, probiotics, or during the test period. However, if you are taking the drug, you can take the test after two weeks of abstinence.
- •If the systolic blood pressure measured at Visit 1 is greater than 160 mmHg or diastolic blood pressure is greater than 100 mmHg and hypertension is not controlled regardless of whether the medication is administered or not.
- •Patients with uncontrolled endocrine diseases (such as diabetes), metabolic diseases (e.g. secondary hyperlipidemia) or hypothyroidism (subjects with a history of hypothyroidism) should receive a stable thyroid hormone supplement for at least 4 weeks prior to visit 1 If you are on therapy, you can participate in this test only if the TSH level measured at Visit 2 is within the normal range.)
- •If kidney function is impaired at visit 1 (creatinine> 2.0 mg / dL) or nephrotic syndrome is observed
- •If the cancer has developed within the past 5 years (unless it is determined to be cured)
- •If there is a history of mental instability and drug / alcohol abuse within the past 5 years, or if major psychiatric illnesses are not adequately controlled and stabilized by medication
- •Visits 1 If you have taken mental nerve agents within the previous 3 months
- •If you take a systemic steroid preparation within 1 month before visit 1
- •Patients who underwent abdominal surgery except for appendectomy, hernia surgery, and cesarean section
- •Any person deemed inappropriate for the judgment of the clinician
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Dietary Supplement)
gQ-lab daily
Experimental
干预措施: gQ-lab daily (Dietary Supplement)
结局指标
主要结局
Symptom questionnaire survey (VAS score)
时间窗: 4 weeks
To assess satisfaction with overall improvement in bowel symptoms, after 4 weeks of administration of GQ lab to patients with irritable bowel syndrome (IBS). The range of the VAS score is 1 to 10. The lower the value of the VAS score, the better. The value of the endpoint (4 weeks) is compared in the placebo group versus the treatment group.
次要结局
未报告次要终点
研究者
相似试验
终止
不适用
A Gastrointestinal Quality of Life Study in Lung Transplant Recipients Converted From Mycophenolate Mofetil to MyforticLung TransplantationNCT01044667Vanderbilt University3
终止
不适用
Evaluation of Gastrointestinal Symptoms and Quality of Life in Patients With Sphincter of Oddi DysfunctionSphincter of Oddi DysfunctionAbdominal PainNCT01410071Wisconsin Center for Advanced Research153
已完成
2 期
BezFAOD continuous clinical studyJPRN-jRCTs011180008shiraishi hideaki7
已完成
不适用
Direct Improvement of Quality of Life Using a Tailored Pathway With Quality of Life Diagnosis and Therapy: Randomised Trial in Colorectal Cancer PatientsQuality of LifeColorectal NeoplasmsNCT02321813Tumor Center Regensburg220
已完成
不适用
A prospective, non-interventional, multicenter observational study on quality of life, documentation of key allergic symptoms/medication and application patterns of SLIT LAIS® cat in patients with cat allergy.J30.3H10.1H10.8J45.0Other allergic rhinitisAcute atopic conjunctivitisOther conjunctivitisPredominantly allergic asthmaDRKS00025314ofarma Deutschland GmbH111